All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
C-C Chemokine receptor type 6 (CCR6) antagonists have been reported in a recent Idorsia Pharmaceuticals Ltd. patent as potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.